Company profile for Sinntaxis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sinntaxis, founded in 2017 by Lund University scientists and LU Holding AB, is a neuroscience company specializing in stroke recovery therapeutics. Our experienced team combines expertise in neuroscience, pharmaceutical development, and business strategy. We have developed a proprietary discovery platform for preclinical stroke research and hold intellectual property on negative allosteric modulators of mGluR5 for post-stroke ...
Sinntaxis, founded in 2017 by Lund University scientists and LU Holding AB, is a neuroscience company specializing in stroke recovery therapeutics. Our experienced team combines expertise in neuroscience, pharmaceutical development, and business strategy. We have developed a proprietary discovery platform for preclinical stroke research and hold intellectual property on negative allosteric modulators of mGluR5 for post-stroke recovery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Stora Gråbrödersgatan 3A, 222 22 Lund
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/04/30/3070940/0/en/Addex-Enters-Option-Agreement-with-Sinntaxis-for-an-Exclusive-License-to-Intellectual-Property-Covering-the-Use-of-mGlu5-Inhibitors-in-Brain-Injury-Recovery.html

GLOBENEWSWIRE
30 Apr 2025
Sinntaxis bags option on ex-AstraZeneca mGluR5 antagonist
Sinntaxis bags option on ex-AstraZeneca mGluR5 antagonist

10 Oct 2018

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/sinntaxis-bags-option-ex-astrazeneca-mglur5-antagonist

Nick Paul Taylor FIERCE BIOTECH
10 Oct 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty